IS7420A - Iressa lyfjablanda sem felur í sér vatnsleysanlega sellulósaafleiðu - Google Patents

Iressa lyfjablanda sem felur í sér vatnsleysanlega sellulósaafleiðu

Info

Publication number
IS7420A
IS7420A IS7420A IS7420A IS7420A IS 7420 A IS7420 A IS 7420A IS 7420 A IS7420 A IS 7420A IS 7420 A IS7420 A IS 7420A IS 7420 A IS7420 A IS 7420A
Authority
IS
Iceland
Prior art keywords
irresistant
containing water
cellulose derivative
formulation containing
soluble cellulose
Prior art date
Application number
IS7420A
Other languages
English (en)
Other versions
IS2462B (is
Inventor
Richard Gellert Paul
Davis Parker Michael
De Matas Marcel
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27767732&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS7420(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0204392A external-priority patent/GB0204392D0/en
Priority claimed from GB0212462A external-priority patent/GB0212462D0/en
Priority claimed from GB0213267A external-priority patent/GB0213267D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IS7420A publication Critical patent/IS7420A/is
Publication of IS2462B publication Critical patent/IS2462B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IS7420A 2002-02-26 2004-08-24 Iressa lyfjablanda sem felur í sér vatnsleysanlega sellulósaafleiðu IS2462B (is)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0204392A GB0204392D0 (en) 2002-02-26 2002-02-26 Pharmaceutical compound
GB0212462A GB0212462D0 (en) 2002-05-30 2002-05-30 Pharmaceutical compound
GB0213267A GB0213267D0 (en) 2002-06-11 2002-06-11 Pharmaceutical composition
PCT/GB2003/000803 WO2003072139A1 (en) 2002-02-26 2003-02-24 Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative

Publications (2)

Publication Number Publication Date
IS7420A true IS7420A (is) 2004-08-24
IS2462B IS2462B (is) 2008-11-15

Family

ID=27767732

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7420A IS2462B (is) 2002-02-26 2004-08-24 Iressa lyfjablanda sem felur í sér vatnsleysanlega sellulósaafleiðu

Country Status (30)

Country Link
US (2) US20050163835A1 (is)
EP (1) EP1480679B1 (is)
JP (1) JP4544863B2 (is)
KR (2) KR101002374B1 (is)
CN (1) CN1326569C (is)
AR (1) AR038848A1 (is)
AT (1) ATE362771T1 (is)
AU (1) AU2003208444B2 (is)
BR (1) BRPI0307786B8 (is)
CA (1) CA2476587C (is)
CO (1) CO5601038A2 (is)
CY (1) CY1108026T1 (is)
DE (1) DE60313956T2 (is)
DK (1) DK1480679T3 (is)
ES (1) ES2286406T3 (is)
HK (1) HK1070585A1 (is)
IL (2) IL163642A0 (is)
IS (1) IS2462B (is)
MX (1) MXPA04008307A (is)
MY (1) MY135609A (is)
NO (1) NO328658B1 (is)
NZ (1) NZ534513A (is)
PL (1) PL208114B1 (is)
PT (1) PT1480679E (is)
RU (1) RU2318518C2 (is)
SA (1) SA03240043B1 (is)
TW (1) TWI271193B (is)
UA (1) UA76325C2 (is)
UY (1) UY27682A1 (is)
WO (1) WO2003072139A1 (is)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ534871A (en) 2002-02-26 2007-05-31 Astrazeneca Ab Novel crystalline forms of the anti-cancer compound ZD1839
GB0317663D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Pharmaceutical composition
PL1746999T3 (pl) 2004-05-06 2012-07-31 Warner Lambert Co 4-fenyloaminochinazolin-6-yloamidy
PT1928409E (pt) 2005-09-12 2012-11-27 Actelion Pharmaceuticals Ltd Composição farmacêutica estável que compreende uma pirimidina-sulfamida
EP3594248B1 (en) 2006-10-27 2021-08-04 Capsugel Belgium NV Hydroxypropyl methyl cellulose hard capsules and process of manufacture
JP5627455B2 (ja) * 2007-06-06 2014-11-19 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 速崩性錠剤製造のための医薬製剤
MX2010001837A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
US8728516B2 (en) * 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
TWI471321B (zh) * 2009-06-08 2015-02-01 Abbott Gmbh & Co Kg Ｂｃｌ－２族群抑制劑之口服醫藥劑型
TWI532484B (zh) * 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
EP2448563A2 (en) * 2009-07-02 2012-05-09 Wyeth LLC 3-cyanoquinoline tablet formulations and uses thereof
SG10201500152UA (en) * 2009-12-22 2015-03-30 Abbvie Inc Abt-263 capsule
JP4574742B1 (ja) * 2010-04-08 2010-11-04 有限会社ミールジャパン プロポリス組成物
EP2632436B1 (en) 2010-10-29 2018-08-29 Abbvie Inc. Solid dispersions containing an apoptosis-inducing agent
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
US20120129853A1 (en) 2010-11-23 2012-05-24 Abbott Laboratories Methods of treatment using selective bcl-2 inhibitors
WO2012071340A1 (en) 2010-11-23 2012-05-31 Metamagnetics Inc. Antenna module having reduced size, high gain, and increased power efficiency
ES2644230T3 (es) 2010-11-23 2017-11-28 Abbvie Inc. Sales y formas cristalinas de un agente inductor de apoptosis
CN102631347B (zh) * 2012-05-03 2014-06-25 石药集团中奇制药技术（石家庄）有限公司 一种吉非替尼药物组合物及其制备方法
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
KR101332829B1 (ko) * 2013-05-31 2013-11-27 재단법인 통합의료진흥원 보중익기탕을 포함하는 폐암 치료용 조성물
GB201400034D0 (en) 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
KR101721831B1 (ko) * 2014-11-06 2017-03-31 주식회사 종근당 로베글리타존을 함유하는 경구 투여용 약제학적 조성물
US20180000827A1 (en) * 2014-12-19 2018-01-04 Synthon B.V. Pharmaceutical composition comprising gefitinib
PL3263110T3 (pl) * 2015-02-26 2023-11-06 Takeda Pharmaceutical Company Limited Tabletka zawierająca pochodną metoksymocznika i cząstki mannitolu
KR101739731B1 (ko) * 2015-12-31 2017-05-25 환인제약 주식회사 유당불내성 환자에게 투여가 가능하며, 복용편의성이 향상된 게피티니브를 함유하는 약제학적 조성물
CN108096251B (zh) * 2016-11-24 2021-11-16 江苏恒瑞医药股份有限公司 一种吉非替尼药物组合物及其制备方法
CN107007562B (zh) * 2017-02-16 2020-10-27 南京优科制药有限公司 一种吉非替尼片剂及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3608063A (en) * 1969-08-15 1971-09-21 Gilbert S Banker Molecular drug entrapment process and compositions
US4178376A (en) * 1977-01-21 1979-12-11 Interx Research Corporation Method for inducing rapid therapeutically effective antimalarial levels of certain selected conventional antimalarials
US4344934A (en) * 1978-11-20 1982-08-17 American Home Products Corporation Therapeutic compositions with enhanced bioavailability
US4704284A (en) * 1982-08-12 1987-11-03 Pfizer Inc. Long-acting matrix tablet formulations
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
GB9207988D0 (en) * 1992-04-10 1992-05-27 Smithkline Beecham Plc Topical composition
JPH09501947A (ja) * 1993-08-30 1997-02-25 ワーナー−ランバート・コンパニー 改良された錠剤コーティング方法
US5559158A (en) * 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB2306885B (en) * 1995-11-08 1999-07-14 Reckitt & Colmann Prod Ltd Supersaturated Pharmaceutical Compositions
AU743024B2 (en) * 1997-03-05 2002-01-17 Sugen, Inc. Formulations for hydrophobic pharmaceutical agents
EP0901786B1 (en) * 1997-08-11 2007-06-13 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailability
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DE19911509A1 (de) * 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
CA2359945C (en) * 1999-11-12 2011-04-26 Abbott Laboratories Inhibitors of crystallization in a solid dispersion
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
KR100397792B1 (ko) * 2001-06-28 2003-09-13 한국과학기술연구원 4-(페닐아미노)-[1,4]디옥사노[2,3-ｇ]퀴나졸린 유도체 및그의 제조방법
NZ534871A (en) * 2002-02-26 2007-05-31 Astrazeneca Ab Novel crystalline forms of the anti-cancer compound ZD1839
KR20050104152A (ko) 2004-04-28 2005-11-02 최승호 경구용 약물의 흡수를 증진하는 약제학적 조성물

Also Published As

Publication number Publication date
UA76325C2 (uk) 2006-07-17
CN1638805A (zh) 2005-07-13
HK1070585A1 (en) 2005-06-24
PL372215A1 (en) 2005-07-11
JP4544863B2 (ja) 2010-09-15
KR20100090726A (ko) 2010-08-16
TW200304379A (en) 2003-10-01
RU2318518C2 (ru) 2008-03-10
AU2003208444B2 (en) 2006-10-26
CA2476587C (en) 2010-05-04
WO2003072139A1 (en) 2003-09-04
CN1326569C (zh) 2007-07-18
ES2286406T3 (es) 2007-12-01
TWI271193B (en) 2007-01-21
AR038848A1 (es) 2005-01-26
KR20040088524A (ko) 2004-10-16
DE60313956T2 (de) 2008-05-15
CA2476587A1 (en) 2003-09-04
RU2004129280A (ru) 2005-06-10
NO20043866L (no) 2004-09-15
IS2462B (is) 2008-11-15
BRPI0307786B8 (pt) 2021-05-25
NO328658B1 (no) 2010-04-19
MXPA04008307A (es) 2004-11-26
PT1480679E (pt) 2007-07-18
CO5601038A2 (es) 2006-01-31
SA03240043B1 (ar) 2007-05-06
NZ534513A (en) 2007-04-27
AU2003208444A1 (en) 2003-09-09
PL208114B1 (pl) 2011-03-31
KR101002374B1 (ko) 2010-12-17
ATE362771T1 (de) 2007-06-15
EP1480679B1 (en) 2007-05-23
EP1480679A1 (en) 2004-12-01
MY135609A (en) 2008-05-30
IL163642A0 (en) 2005-12-18
US20090186890A1 (en) 2009-07-23
BR0307786A (pt) 2004-12-07
IL163642A (en) 2007-07-24
JP2005523293A (ja) 2005-08-04
CY1108026T1 (el) 2013-09-04
BRPI0307786B1 (pt) 2018-03-13
DK1480679T3 (da) 2007-09-03
DE60313956D1 (de) 2007-07-05
UY27682A1 (es) 2003-10-31
US20050163835A1 (en) 2005-07-28

Similar Documents

Publication Publication Date Title
IS2462B (is) Iressa lyfjablanda sem felur í sér vatnsleysanlega sellulósaafleiðu
IS2946B (is) Lyfjablanda sem felur í sér andrógen
IS2732B (is) Fenýl-píperidín afleiður sem serótónín endurupptökuhindrar
HK1071360A1 (en) 2-hydroxy-3-heteroarylindole derivatives as gsk3 inhibitors
AU2003260345A1 (en) 2-phenylpyridin-4-yl derivatives as alk5 inhibitors
IS6313A (is) Bíarýl eter afleiður nytsamlegar sem mónóamín endurupptöku latar
IS6890A (is) Innstunguefni, sem innihalda epóþílon hliðstæður
IS2529B (is) Nýjar spírótrísýklískar afleiður og notkun þeirra sem fosfódíesterasa-7-hindrar
HK1089436A1 (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
IS8351A (is) Lyfjaafurðir sem fela í sér bisfosfónöt
IS8480A (is) Öragnir sem fela í sér sómatóstatínhliðstæður
IS2458B (is) Indólín-2-ón afleiður, framleiðsla og notkun þeirra sem mjaltavaka (ocytocin) viðtakabindlar
IS7509A (is) Þíoxantínafleiður sem mergperoxídasatálmar
IS7077A (is) Kristölluð samsetning sem inniheldur essítalópram
IS8287A (is) Lyfjablanda sem felur í sér levóþýroxínnatríum
IS7177A (is) Valdekoxíb samsetningar sem leysast upp í munni
AU2003298659A8 (en) Soluble isoflavone compositions
IL172023A0 (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
IS8117A (is) 3-Flúr-píperidín sem NMDA/NR2B mótlyf
AU2002223968A1 (en) Piperidine derivatives as subtype selective n-methyl-d-aspartate antagonists
ZA200509869B (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
IS2456B (is) Ímídasókínólínafleiður sem adenósín A3 viðtakabindlar
IS7488A (is) Dreyfasamsetning í föstu formi
IS7303A (is) 3-fenýl-2-arýlalkýlþíóprópíónsýruafleiður sem valvís gerandefni PPAR-ALFA
AU2003275009A8 (en) Methods for manufacturing polysaccharide derivatives